Comparative Pharmacology
Head-to-head clinical analysis: SLO PHYLLIN versus VOSPIRE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SLO PHYLLIN versus VOSPIRE ER.
SLO-PHYLLIN vs VOSPIRE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular cAMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.
Vospire ER (albuterol sulfate) is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via activation of adenylyl cyclase, leading to bronchodilation.
Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/mL.
Oral: 30-60 mg once daily in the morning, with or without food. Maximum dose: 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 3-8 hours in adults (non-smokers, healthy), 1-5 hours in smokers, and 20-30 hours in neonates. Clinical context: Half-life is prolonged in hepatic cirrhosis, heart failure, and with certain drug interactions (e.g., cimetidine, ciprofloxacin).
Terminal elimination half-life of vospire ER is approximately 12-15 hours. This prolonged half-life supports once-daily dosing and provides sustained bronchodilation over the dosing interval.
Renal: ~10% unchanged; hepatic metabolism accounts for ~90% of elimination, with metabolites excreted in urine. Fecal: <5%.
Primarily renal (approximately 75% as unchanged drug and metabolites) and biliary/fecal (approximately 25%).
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator